Indivior Pharmaceuticals, Inc. (INDV): EBITDA
$272.00M
Year ended 2025-12-31
$430.00M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $272.00M | +403.7% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $54.00M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$137.00M | n/c | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$65.00M | n/a | 2025-03-03, From 2022-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $272.00M | +403.7% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $340.68M | -7.2% |
| Alkermes plc. (ALKS) | 2025-12-31 | $281.12M | -37.4% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $245.91M | +57.6% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | -$298.59M | n/m |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $905.75M | n/m |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $202.51M | +196.4% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $120.55M | n/m |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $45.95M | -66.6% |
Compare INDV, PBH, ALKS, PAHC side by side · Screen every company in Pharmaceutical Preparations ↗